Organisation paid for research Program year 2023 Source: CMS Open Payments

Spring Gastroenterology

Neither a doctor nor a teaching hospital

Research payments

$192,000

13 payments

Through program year 2023, Spring Gastroenterology is reported as receiving $192,000 in research payments, across 13 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$36,938	2
2022	Research	$10,051	1
2021	Research	$10,697	2
2020	Research	$48,219	3
2019	Research	$86,096	5

Breakdown

Who paid Research payments · program years 2019–2023

E.R. Squibb & Sons, L.L.C. $192,000 12 payments
Allergan Inc. $0 1 payment

Studies the money was for Research payments · program years 2019–2023

Phase IIB Study - F3 24 wk $38,375 1 payment
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease $32,950 1 payment
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis $32,476 3 payments
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis $26,233 3 payments
Phase IIB Study - F4 48 wk $22,464 1 payment
Phase 2 UC $20,506 1 payment
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Compensated Liver Cirrhosis $14,246 1 payment
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease $4,750 1 payment
A Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Medi2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed Or Are Intolerant to Anti-Tumor Necrosis Factor-Alpha Therapy $0 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.